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Abstract
Background: Smoking cessation can significantly reduce the risk of developing smoking-related diseases. Several
face-to-face and web-based treatments have shown to be effective. Blending of web-based and face-to-face treatment
is expected to improve smoking cessation treatment. The primary objective of this study is to compare the prolonged
abstinence rate of the blended smoking cessation treatment with the face-to-face treatment. Secondary objectives are
to assess the benefits of blended treatment in terms of cost effectiveness and patient satisfaction, and to identify
mechanisms underlying successful smoking cessation.
Methods/Design: This study will be a single-center randomized controlled non-inferiority-trial with parallel group
design. Patients (n = 344) will be randomly assigned to either the blended or the face-to-face group. Both treatments
will consist of ten sessions with equal content held within 6 months. In the blended treatment five out of ten sessions
will be delivered online. The treatments will cover the majority of behavior change techniques that are evidence-based
within smoking cessation counseling. All face-to-face sessions in both treatments will take place at the outpatient smoking
cessation clinic of a hospital. The primary outcome parameter will be biochemically validated prolonged abstinence at
15 months from the start of the smoking cessation treatment.
Discussion: This RCT will be the first study to examine the effectiveness of a blended smoking cessation treatment. It will
also be the first study to explore patient satisfaction, adherence, cost-effectiveness, and the clinically relevant influencing
factors of a blended smoking cessation treatment. The findings of this RCT are expected to substantially strengthen the
base of evidence available to inform the development and delivery of smoking cessation treatment.
Trial registration: Nederlands Trialregister NTR5113. Registered 24 March 2015.
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Background
Killing nearly six million people a year, smoking tobacco is
one of the biggest public health threats. Of the smokers
who are aware of the dangers of tobacco the majority want
to quit [1]. Although a proportion of smokers quit without
professional support [2], counseling and medication can
more than double the success rate [1]. Success rates of
smoking cessation treatments (5-months-after-treatment)
range between 8,5% (minimal or no counseling or self-
help) and 27,6% (intense counseling & medication) [3],
depending on (1) contact time and intensity, (2) number
and length of sessions, (3) number and type of clinicians
involved, and (4) number and type of counselling formats
and interventions. A treatment comparable to the ones of
this trial has shown to lead to a cotinine-validated
prolonged 12 months’ abstinence rate of 10% (based on
intention-to-treat analysis) [4, 5].
Traditionally, smoking cessation treatment is offered as
face-to-face counseling. With the rise of the internet,
web-based treatment offers an additional channel for
effective smoking cessation [6]. Nowadays face-to-face
treatment and web-based treatment are usually offered
separately. An integration of web-based and face-to-face
treatments (blended treatment) is expected to combine
the “best of both worlds” [7] as this will allow the
strengths of one to offset the weaknesses inherent in the
other [8].
The weaknesses of face-to-face treatment that can be
offset by the strengths of web-based treatment refer to
(1) therapist drift; (2) patients’ no-show and (3) travel
costs. (1) Face-to-face treatments often suffer from
therapist drift [9]. This drift can be reduced by the pro-
tocolled nature of web-based treatments, which have
shown to lead to higher treatment integrity [10]. (2)
Patients’ no-shows result in time lost both for the coun-
selors and the patients. In BSCT counselors can replace
patients not showing up with online work, which can be
planned flexibly as the process of online communication
with the patients occurs asynchronously. Patients that
miss a face-to-face session can still access their personal
online dossier and continue treatment autonomously
(e.g. psycho-education, exercises, and summaries of
counseling conversations). As both counselors and
patients can use their time more efficiently this can re-
sult in offering treatment to more patients [11]. (3)
Travelling to the smoking cessation clinic to attend a
face-to-face meeting with the counselors is both time
consuming and costly for the client. Web-based sessions
do not require showing up at the clinic during the
normal business hours, because they can be done e.g. at
home in the evening. This reduces work time lost as well
as travel related costs for the patients [9, 12].
The weaknesses of web-based treatment that can be
offset by the strengths of face-to-face treatment refer to
(1) poor engagement of patients and (2) tailoring of
interventions. (1) A common problem of web-based
treatment is poor engagement of users due to the small
amount of personal contact [13]. Face-to-face treatment
offers more personal contact and may therefor result in
a higher commitment of the patients. (2) Web-based
treatments are supposed to offer more tailoring [6].
Face-to-face treatment can offer greater flexibility in
customizing interventions to the patients’ needs by for
example explaining therapeutic interventions or provid-
ing additional information for diagnostic purpose or case
management [9, 14, 15].
To the best of our knowledge there has been no
research on the potential benefits of a blended treatment
for smoking cessation. The primary objective of this
research is to find out if a blended smoking cessation
treatment (BSCT) results in non-inferior quit rates com-
pared to a face-to-face treatment as usual (TAU).
Secondary objectives are to assess whether (1) patients
are more satisfied with BSCT; (2) BSCT reduces
treatment costs; (3) there is link between quitting and
adherence in BSCT; (4) there are moderators or media-
tors predicting treatment outcome; and (5) how the
treatment can further be improved.
Methods/Design
The study will be a single-centre randomized controlled
non-inferiority trial with a parallel group design.
Study population
The study population will consist of the patients of the
outpatient smoking cessation clinic at Medisch
Spectrum Twente (MST), Enschede, The Netherlands.
These patients will be referred to the clinic by treating
physicians of the hospital or by their GPs.
Inclusion/Exclusion criteria
Participants of this study will be smokers who admit
themselves to the cessation clinic (indicating readiness
to quit), who are at least 18 years old, who are
currently daily smokers (at least one cigarette/day),
and who are able to both access websites and com-
municate by email (both verified during intake pro-
cedure by asking whether the participant has internet
access at home, and a current email address). People
who are not able to read or write in the Dutch
language will be excluded from this study.
Recruitment
Participant will be recruited from those patients that
have signed up for smoking cessation treatment at the
outpatient smoking cessation clinic. Based on earlier
studies and the criteria for participation, we expect that
a majority of patients will be eligible for this study.
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Participation in the study will be voluntary and patients
will not receive any payment for participation.
Randomization
Patients will be randomly assigned to either BSCT or
TAU. Randomization will be performed at the individual
level (allocation ratio 1:1) using QMinim Online
Minimization (http://qminim.sourceforge.net/) [16]. The
minimization will be stratified according to: (1) level of
internet skills [17]; (2) level of nicotine dependence [18]);
and (3) the quitting strategy favored by the patient (stop at
once, gradual change, scheduled reduced smoking; for
details see below the description of the study interven-
tion). The data used for the QMinim minimization will be
collected using the baseline questionnaire, which will be
filled in online by the patient at home.
Blinding
The study will be an open label study, as it is self-
evidently impossible (due to the nature of the treatment
conditions) to blind the staff and patients that are
involved.
Study intervention
BSCT will be a combination of face-to-face treatment
combined with web-based treatment into one integrated
smoking cessation treatment that can be delivered in
conventional smoking cessation clinics [12, 14]. Both
BSCT and TAU will be provided by the Outpatient
Smoking Cessation Clinic (SRP), which is part of the
Department of Pulmonary Medicine of MST hospital.
The web-based interaction of BSCT – which patients
will do e.g. at home - will make use of Tactus Addiction
Treatment’s website http://www.rokendebaas.nl. Out of
this web-based treatment five session have been adopted
for the integration in BSCT (Table 1). The SRP team
consists of a pulmonologist and three qualified stop-
smoking counsellors. The counsellors are registered on
the Dutch Quality Register of qualified smoking cessation
counsellors (http://www.kwaliteitsregisterstopmetroken.nl).
Both treatments fulfil the requirements of the Dutch
care module for smoking cessation [19] which is de-
rived from the evidence-based Dutch Guideline Treat-
ment Tobacco Addiction [20]. The costs of smoking
cessation treatment will be reimbursed by the
patient’s health care insurance.
TAU is personalized to the patients’ needs and
contains flexibility in quitting strategies. To allow for
comparability this flexibility is also integrated in BSCT.
At treatment start the patients will be asked to favor one
of three quitting strategies:
(1)Stop at once: the patient sets a quit date, makes a
preparation plan and stops abruptly on the quit date.
(2)Gradual change: the patient selects daily activities
and contexts in which smoking is habitual and
step-by-step continues these activities smoke free
(for example when reading newspaper, Facebook,
reading email, drinking coffee); finally, the patient
sets a quit date. Being already accustomed to a
range of daily habits without smoking will make it
easier for the patient not to relapse.
(3)Scheduled reduced smoking [21]: the patient
gradually decreases the number of cigarettes at
regular intervals; at the start the patient does not
smoke less but becomes used to a fixed schedule,
and in subsequent phases the number of cigarettes
will be gradually reduced (100%→ 75%; 75%→ 50%;
50%→ 25%) until the patient is ready to stop
completely. This strategy systematically deconditions
the cues. Although recent studies [22, 23] suggest that
gradual cessation strategies – such as scheduled
reduced smoking - may be sub-optimal compared to
abrupt cessation, gradual cessation is still superior to
non-treatment [21]. Offering scheduled reduced
smoking broadens the target group for the cessation
clinic, as it also allows patients who are initially
reluctant to quit abruptly to enroll. Further, as it is an
established part of TAU in this clinical setting, gradual
cessation needs to be included in BSCT as well.
Both BSCT and TAU will consist of ten sessions with
similar content spread over 6 months, with the fre-
quency of sessions fading over time (six sessions within
the first 3 months, four sessions within the final 3
months). Although participants may choose their pre-
ferred quitting strategy, this only marginally affects the
content of the actual treatment that is delivered. Regard-
less of quitting strategy, the number and order of
sessions is identical, as well as the effective components:
the behavioral change techniques applied within sessions
do not vary systematically. However, within the early
sessions some differences may occur on a more detailed
level within the BCTs (e.g. the timing of goal achieve-
ment within goal setting), due to quitting strategy.
All TAU sessions will take place at the SRP clinic while
BSCT sessions will take place alternately face-to-face at
the SRP (five sessions) and online (five sessions). This
blended protocol resulted from a user centered design
approach in which experts and counselors were involved
in developing the most suitable mix of both delivery
modes. The 50–50% blend of face-to-face and web-based
sessions results in a considerable substitution by web-
based interaction, while at the same time maintaining
the intensity of the full intervention.
As in TAU, BSCT consists of both counselor-
dependent and counselor-independent components. The
counselor-dependent web-based components of BSCT
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Table 1 Distribution of the behaviour change techniques in the face-to-face and online session in BSCT and TAU
Session/week Name (Code) of the main behavioural change techniques according to [20] TAU BSCT
Session 1, week 1
Goal setting
Provide information on consequences of smoking and smoking
cessation (BM1)
Provide rewards contingent on successfully stopping smoking (BM4)
Identify reasons for wanting and not wanting to stop smoking (BM9)
Facilitate goal setting (BS4)
Prompt self-recording (BS6)
Advise on stop-smoking medication (A1)
Advise on/facilitate use of social support (A2)
Build general rapport (RC1)
Explain expectations regarding treatment programme (RC4)
Face-to-face Face-to-face
Session 2, week 3
Measures for self-control
Provide feedback on current behaviour (BM3)
Provide rewards contingent on effort or progress (BM7)
Facilitate barrier identification and problem solving (BS1)
Facilitate relapse prevention and coping (BS2)
Prompt review of goals (BS5)
Prompt self-recording (BS6)
Advise on changing routine (BS7)
Tailor interactions appropriately (RD1)
Face-to-face Online
Session 3, week 5
Dealing with withdrawal
Provide feedback on current behaviour (BM3)
Provide normative information about others’ behaviour and
experiences (BM5)
Facilitate relapse prevention and coping (BS2)
Prompt self-recording (BS6)
Provide information on withdrawal symptoms (RC6)
Provide reassurance (RC10)
Face-to-face Face-to-face
Session 4, week 7
Breaking habits
Provide feedback on current behaviour (BM3)
Provide normative information about others’ behaviour and
experiences (BM5)
Facilitate barrier identification and problem solving (BS1)
Facilitate relapse prevention and coping (BS2)
Advise on changing routine (BS7)
Advise on conserving mental resources (BS10)
Advise on avoiding social cues for smoking (BS11)
Advise on/facilitate use of social support (A2)
Provide reassurance (RC10)
Face-to-face Online
Session 5, week 9
Dealing with triggers
Provide rewards contingent on effort or progress (BM7)
Facilitate relapse prevention and coping (BS2)
Face-to-face Face-to-face
Session 6, week 11
Food for thought
Provide feedback on current behaviour (BM3)
Offer/direct towards appropriate written materials (RC5)
Elicit client views (RC8)
Face-to-face Online
Session 7, week 14
Think differently
Provide feedback on current behaviour (BM3)
Measure CO (BM11)
Facilitate barrier identification and problem solving (BS1)
Facilitate relapse prevention and coping (BS2)
Prompt self-recording (BS6)
Build general rapport (RC1)
Elicit and answer questions (RC2)
Face-to-face Face-to-face
Session 8, week 18
Do differently
Provide feedback on current behaviour (BM3)
Facilitate barrier identification and problem solving (BS1)
Facilitate relapse prevention and coping (BS2)
Prompt self-recording (BS6)
Tailor interactions appropriately (RD1)
Build general rapport (RC1)
Face-to-face Online
Session 9, week 22
Action plan
Provide feedback on current behaviour (BM3)
Measure CO (BM11)
Facilitate action planning/develop treatment plan (BS3)
Build general rapport (RC1)
Elicit client views (RC8)
Face-to-face Face-to-face
Session 10, week 26
Closure
Provide feedback on current behaviour (BM3)
Provide rewards contingent on successfully stopping smoking (BM4)
Strengthen ex-smoker identity (BM8)
Facilitate barrier identification and problem solving (BS1)
Facilitate relapse prevention and coping (BS2)
Face-to-face Online
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are interactive and rely on (asynchronous) communica-
tion between counselor and patient. The counselor-
independent components such as psycho-educational
content or the smoking diary are used by the patients on
their own and in their own time. In TAU these compo-
nents are provided in a paper manual that clients take
home. In BSCT, these components are accessible online.
As such, both treatments are equivalent with regard to
both content and intensity. An additional benefit of
BSCT, though, is that the content of previous counselor-
dependent components remains accessible as email
correspondence saved online.
Both BSCT and TAU will cover the majority of the
behavior change techniques that are used within individ-
ual behavioral support for smoking cessation [24],
including those techniques that have shown to be reli-
ably associated with better quit outcomes [25]. The
distribution of the main behavior change techniques and
the distribution of the face-to-face and web-based
session are shown in Table 1.
Measurements
The time-points of the follow-up measurements are tied
to the estimated stop-date, which is appropriate for
aid-to-cessation trials [26]. The expected stop-date is 3
months after treatment start, which is later than in
common cessation treatments where quitting usually is
expected within 1 to 3 weeks. In total there will be four
follow-up measurements with measurement 3 and 4 (9
and 15 months follow-up) to be conducted at standard
time points (i.e. 6 and 12 months after the expected
stop-date):
(1)3 months after treatment start, expected stop-date,
(3 months follow-up);
(2)6 months after treatment start, end of treatment and
3 months after expected stop-date, (6 months
follow-up);
(3)9 months after treatment start, 3 months after end
of treatment, 6 months after expected stop-date,
(9 months follow-up); and
(4)15 months after treatment start, 9 months after end
of treatment, 12 months after expected stop-date,
(15 months follow-up).
A measurement schedule can be found in Table 2. The
biochemical measurements will be done when the
patient is at the hospital for a face-to-face session in week
1 (Exhaled CO; baseline/month 0), week 14 (Exhaled CO
& Cotinine level; month 3) and week 22 (Exhaled CO;
month 5). For the final biochemical measurement (Ex-
haled CO & Cotinine Level; month 15) which will take
place 12 month after the expected stop date in month 3,
the patient will have to return to the hospital. All other
assessments will be done using online questionnaires
which the patients will complete at home.
The CO measurements in the study will serve as a
backup for the cotinine measurements. They will only be
analyzed in case the saliva samples are not usable.
This backup strategy has been chosen because CO
measurements are part of the routine stop-smoking treat-
ment. To keep the burden for the participating patients as
low as possible the measurements are linked to the sched-
uled face-to-face sessions. As the last face-to-face session
in both treatment groups usually takes place in week 22
this moment has been chosen for the measurement to
prevent the patient from travel time/work time loss for an
extra appointment because of the study.
During the informed consent procedure all partici-
pants will receive a patient information letter that out-
lines the burden of participation, including the online
questionnaires. By stressing the importance of the
online questionnaires we try to increase patient com-
mitment. During the trial, completion of the ques-
tionnaires will be checked after 2 weeks. Participants
not completing the questionnaire will receive four
weekly reminders: first twice via email, then twice by
telephone. If a participant signals to be struggling
with completing the questionnaire online, we will
offer a paper version of the questionnaire, which will
be sent including a return envelope.
Instruments
Primary outcome (Cotinine level)
The primary outcome parameter will be biochemically
validated prolonged abstinence [26] at 15 months from
the start of the smoking cessation treatment. Saliva
cotinine level will be measured as biochemical verification
of abstinence only by those patients that report quitting
Table 1 Distribution of the behaviour change techniques in the face-to-face and online session in BSCT and TAU (Continued)
Facilitate goal setting (BS4)
Set graded tasks (BS9)
Advise on/facilitate use of social support (A2)
Build general rapport (RC1)
Offer/direct towards appropriate written materials (RC5)
Elicit client views (RC8)
Codes: BM = Specific focus on behaviour (B) and addressing motivation (M); BS = Specific focus on behaviour (B) and maximising self-regulatory capacity/skills (S);
A = Promote adjuvant activities (A); RC = General aspects of the interaction (R) focusing on general communication (C); RD = General aspects of the interaction (R)
focusing on delivery of the intervention (D)
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smoking in the previous online questionnaires [27]. Pro-
longed abstinence is defined as having salivary cotinine
levels < 20 ng/ml [28] that validate both the self- reported
abstinence after the self-chosen stop date – usually 3
months after start - and the self-reported abstinence at
15 month follow-up. Patients not reporting abstinence or
with a higher cotinine level on any of these follow-ups will
be regarded as smokers as well as patients who are lost to
follow-up. A 0,5–1 ml salivary sample will be collected for
cotinine assessment by means of a Salivette (Sarstedt AG
& Co., Nümbrecht, Germany). Under supervision, patients
will have to chew on a cotton swab for 1min to stimulate
the saliva flow rate. All saliva specimens will be frozen
until assayed and transported to the laboratory for




Fagerström Test for Nicotine Dependence (FTND) [29]
is the most commonly used tool for the assessment of
nicotine dependency. The scores obtained on the test
permit the classification of nicotine dependence into five
levels: very low (0 to 2 points); low (3 to 4 points);
moderate (five points); high (6 to 7 points); and very
high (8 to 10 points). The instrument evaluates for
example time from awakening to the day’s first cigarette,
smoking when bed-ridden with illness, and difficulty in
refraining from smoking when prohibited.
MAP-HSS + smoking related complaints of smokers
The MAP-HSS is a ten-item health scale, which was
adapted from the Opiate Treatment Index [30]. Each
item is scored on a five-point Likert-type scale, ranging
from 0 (complaint never present in the previous 30 days)
to 4 (complaint always present in the previous 30 days),
resulting in a total scale-score ranging from 0 to 40. In
addition to MAP-HSS the patients will be asked to scale
16 typical smoking related complaints (for example cold
hands and feet, cough, pale skin, pain in the lung). An
overall score of physical complaints will be calculated by
Table 2 Measurement schedule
Variables Measurement at month
0 3 5 6 9 15
Primary outcome
Cotinine level X X
Secondary outcomes
Nicotine dependence (Fagerström) X X X
MAP-HSS + smoking related complaints of smokers X X X X
Depression, anxiety and stress (DASS21) X X X X
Quality of Life (Euroqol 5D) X X
Smoking status X X X X X
Adherence X
Costs X
Baseline predictors and moderators of treatment effect
Internet Skills X
Readiness to change X
Attitude X X X
Social Influence X
Self-Efficacy X X
Alcohol/substance (mis)use X X
Descriptive variables
Patient characteristics and medical history X
Smoking history X
Stop Smoking History X
Other information of interest
Evaluation of treatment X X X X
Exhaled carbon monoxide (CO) level X X X X
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adding MAP-HSS and the additional smoking related
complaints.
Depression, anxiety and stress (DASS-21)
The DASS21 [31, 32] is a consistent, valid and reliable
set of three self-report scales designed to measure the
negative emotional states of depression, anxiety and
stress. Each of the three DASS scales contains seven
items. Patients will be asked to use 4-point severity/fre-
quency scales to rate the extent to which they have
experienced each state over the past week. Scores for
Depression, Anxiety and Stress will be calculated by
summing the scores for the relevant items.
Quality of life (Euroqol 5D)
The EuroQol-5D [33] is a generic quality-of-life (QoL)
instrument which consists of five domains: mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. There are three response alternatives for
each domain. The EQ-5D index is obtained by means of
applying predetermined weights to the five domains.
The EQ-5D index is a societal-based numerical quantifi-
cation of the patients’ health status which can range
from 0 (death) to 1 (perfect health status). In addition to
the five domains, EuroQol-5D also offers an overall
rating for quality of life by means of a visual analogue
scale (VAS). The VAS is a vertical line from worst (0) to
best state of health (100).
Smoking status
Smoking status comprises self-reported smoking related
variables such as quit attempts (>24 h), number of re-
lapses, or the amount of daily tobacco consumption (cig-
arettes, self-rolled cigarettes, cigarillos, e-cigarettes). All
smoking status variables are based on a standardized
questionnaire for Dutch tobacco research [34].
Adherence
In order to find out how the web-based application is
used, real-time logdata will be collected to track individ-
ual use. These log files will be used for identifying user
profiles and to gain insight into adherence to the appli-
cation, usage patterns that emerge, and what elements of
the application are used. This information will provide
insight in how the application (both content and system)
matches with its users. In addition, information about
the type and number of BCTs taken from the patient’s
record, which is kept by the counsellor, will be analysed
to calculate the level of adherence.
Costs
All direct treatment-related costs generated by the care
providers and the patients: Costs will be calculated
based on hours spent by the counsellors (including for
no shows), patients’ travel costs, and maintenance of the
web-based infrastructure.
Baseline predictors and moderators of treatment effect
Internet skills
Internet skills will be measured using an online ques-
tionnaire based on conceptual definitions for internet
skills [17]. This conceptual definition includes two major
skill areas (medium-related Internet skills and content-
related Internet skills), which contain in total five minor
skill areas. Medium-related Internet skills include oper-
ational (for example operating an Internet browser or a
search engine) and formal (for example maintaining a
sense of location when on the Internet) skills. Content-
related Internet skills include informational (for example
defining search options or queries), communication (for
example searching, selecting, reaching and evaluating
contacts online) and strategic (for example taking advan-
tage of the Internet) skills. A ten item questionnaire [35]
will be used to measure internet skills with a 5-point
Likert scale, resulting in a score range from 10
(unskilled) to 50 (highly skilled).
Readiness to change
Readiness to change will be measured using the
algorithm to detect the stage of change in smokers
[36]. The expected stop moment (within 1 month ver-
sus within 2 or 3 months) offers the possibility to
distinguish between the contemplation and prepar-
ation stage of change.
Attitude, social influence and self-efficacy
According to the ASE Model [37, 38] the intention to
stop smoking is determined by three motivational
factors: Attitude, Social Influence and Self-Efficacy. Atti-
tude [39, 40] refers to the overall evaluation of smoking
cessation. Attitude will be measured with an indirect,
belief-based scale for perceived pros (four items: im-
proved health for the patient, improved health for the
patient’s personal environment, lower risk of lung
cancer, improved self-satisfaction) and cons (four items:
suffering withdrawal symptoms, missing smoking, less
ability to relax, feeling bored). Social influence refers to
three distinctive constructs: social norms, perceived be-
haviour of others and direct support. It will be measured
recording if the patient is stimulated to stop smoking by
acquaintances, if his/her partners is a smoker and how
many of his/her acquaintances are smokers. Self-Efficacy
[41] refers to the confidence in the ability to refrain from
smoking in specific high-risk situations, i.e. the situa-
tions in which the quitter is tempted to relapse. It will
be measured recording six typical relapse situations
(e.g. stress or party). The three constructs of the ASE
model will be measured using standardized questions
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developed by the former Dutch foundation STIVORO
[34, 42].
Alcohol and substance (mis)use
Alcohol (mis)use will be measured using the Five-shot
questionnaire on heavy drinking [43]. Only if a patient
declares that he/she is consuming alcohol/substances at
all, additional questions will be asked to keep the burden
for the patient as low as possible. The additional ques-
tions will record the frequency and amount of alcohol
consumption, feelings of anger and guilt related to
drinking, and if the patient drinks in the morning to
cope with hangover. Substance (mis)use will be mea-
sured asking for (recreational-)drug use in general. If the
patient declares to use (recreational-)drugs additional
questions will ask for type of (recreational-)drug and
frequency and duration of use.
Descriptive variables
Patient characteristics and medical history
Demographical data (sex, age, nationality, cultural back-
ground, marital status, children, housing, education,
source of income, main activity) will be collected using
an online questionnaire. Medical history will be recorded
from medical charts.
Smoking history
Smoking history will be measured using an online
questionnaire from the longitudinal Vlagtwedde-
Vlaardingen Study (1965 to 1990) [44] recording the
age of first smoking attempts and the numbers of
years and number of cigarettes/day that the patient
was smoking in each decade.
Stop smoking history
Earlier attempts to stop smoking will be recorded using
an online questionnaire asking: if there were earlier stop
smoking attempts; when the last stop smoking attempt
was; how long the non-smoking phase was; and when
the last stop smoking attempt was, which was successful
for more than 24 h.
Other information of interest
Evaluation of treatment
Three month after start of the treatment, at the end of
the treatment (6 month after start) and during the
follow-up measurements (9 and 15 month after start)
patients will be asked to report their experiences with
the different aspects of the treatment program. Patients
can rate satisfaction with the program by grading all sep-
arate types of contact, assessing the overall contact with
their counsellors, and reporting their own perception of
improvements. In addition, they will be asked to report
on adherence, results and benefits, gained insights, the
use of co- interventions, and the use of NRT. Further-
more, they will be asked for improvement suggestions.
Exhaled carbon monoxide (CO) level
The measurement of exhaled carbon monoxide (CO)
level provides an immediate, non-invasive method of
assessing smoking status [45]. A breath CO level of
5 ppm is taken as the cut-off between smokers and non-
smokers (5 ppm or higher = smoker, less than 5 ppm =
non-smoker). Breath CO monitoring will be performed
using a piCo Smokerlyzer (Bedfont Instruments: Kent,
UK), a portable CO monitor.
The level of exhaled carbon monoxide (CO) level will
be recorded because the CO measurement is already
part of the treatment so that these data is easily avail-
able. Because the validation of the smoking cessation is
done with cotinine tests (see above) the CO data will
only be used if cotinine measurements are missing and
to provide data for future research such as for example
comparing different measurement techniques.
Sample size
For this RCT 344 patients will be needed. This is based
on the following assumptions and calculations.
Since we expect that BSCT will be at least non-
inferior to TAU concerning prolonged abstinence, we
conduct a non-inferiority trial. Furthermore, we expect
BSCT to be better at secondary factors such as costs, ad-
herence and satisfaction [46].
Based on previous studies involving smoking cessation
treatment within the organization involved in this RCT
[4, 5] and meta analyses [3], a cotinine-validated pro-
longed 12 months’ abstinence rate of 10% (based on
intention-to-treat analysis) with TAU is expected. Based
on the expected benefits of BSCT the estimated abstin-
ence rate for BSCT is 15%. If BSCT leads to an abstin-
ence rate of not lower than 5% it will be regarded as
non-inferior. With a power of 80% and α of 0,025 172
patients per group are needed for this RCT (calculated
with PASS).
The 5% criterion is based on the three assumptions
described below:
(1)A validated prolonged abstinence rate of 5% may still
be considered as superior to (1) a non-intervention
condition which is estimated at a 1.4% abstinence
rate and to (2) a 2.6% abstinence in a minimal
intervention condition in clinical populations such
as COPD patients [47].
(2)In a worst-case scenario, BSCT patients will fail to
use the web-based part of the intervention completely,
and adhere to the face-to-face component only. This
would reduce their exposure to the intervention by
50% compared to full adherence to TAU. Assuming a
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linear dose–response relationship of intervention
intensity and likelihood of abstinence the 10%
abstinence rate estimated for TAU would then be
reduced by 50% to a 5% abstinence rate.
(3)Although a 5% abstinence rate is considerably lower
than the estimated 10% in TAU, the secondary
benefits of BSCT - such as client satisfaction - need
to be taken into account. Thus, even at a lower
effectiveness we expect that BSCT can still be the
preferred treatment.
Based on the experience that approximately 360 patients
per year start a cessation treatment at SRP, it is expected
that recruitment, treatment and follow-measurements of
the 344 patients needed for this RCT will take 3 to 4 years.
Handling of study dropouts
If a subject is prematurely withdrawn or withdraws from
participation in the study for whatever reason, the statis-
tical analysis will be conducted following the intention-
to-treat principle [48], assuming that missing cases are
at their baseline level. This will produce conservative
estimates of smoking abstinence but will still allow for
treatment outcomes that are based on the entire sam-
ple. Patients who fail to keep an appointment will be
contacted and if possible, will be rescheduled for
another appointment, ideally within 7 days of the
missed appointment.
Data management
The handling of personal data will comply with the
Personal Data Protection Act in The Netherlands. Data
will be recorded using the two ways of data collection
described below.
(1)Data from the face-to-face contacts will be recorded
on data collection forms and centrally collected at
Medisch Spectrum Twente. The study data manager
will record all the collected data in a Microsoft
Access 2007 database.
(2)The majority of data will be recorded by Tactus
Addiction Treatment – a regional addiction care
organization with experience in web-based treatment
- using online questionnaires which will be offered
to both treatment groups. Individual patients and
counsellors will have a login with username and
password secured by Secure Sockets Layer to the
application. All data transferred between the patient’s
personal computer and the application will be
encrypted and sent via the https protocol. All data
will be encrypted and stored on servers in secure
data centres within the Netherlands. Daily
backups of the server will be made to ensure
further data security.
Data analysis/Statistical methods
Baseline characteristics will be displayed as means with
standard deviations (SD) or medians with interquartile
range (IQR) for continuous variables depending on the
distribution of the variable; categorical variables will be
displayed as counts with corresponding percentages.
Differences between the two treatment groups in terms
of continuous variables will be tested by the independent
T-test or the Wilcoxon rank sum test, depending on the
distribution of the variable. Differences in categorical
variables will be tested by the Chi-square test or the
Fisher exact test.
The non-inferiority between BSCT and TAU in salivary
cotinine validated 12 months’ prolonged abstinence rate
will be analyzed by calculating the 95% confidence interval
of the observed difference in the abstinence rate and by
comparing that to the previously defined non-inferiority
margin of 5%.
To assess whether BSCT leads to a decrease in treatment
costs compared to TAU, an incremental cost-effectiveness
ratio (ICER) will be calculated using treatment costs and
abstinence rate.
To assess whether BSCT leads to improved satisfac-
tion among patients and counsellors compared to TAU,
satisfaction (based on the middle and long-term evalu-
ation) will be tested between the two groups by applying
the independent T-test or the Wilcoxon rank sum test.
Both baseline predictors - moderators of intervention
effect - and dynamic predictors - mechanisms through
which effects occur - will be tested using moderator and
mediator analyses [49, 50], including all potential co-
variates such as nicotine dependence, cognitive determi-
nants (for example attitude and self-efficacy), medical
conditions and mental states (for example depression
and anxiety), adherence and internet skills.
Whether the level of adherence to BSCT is related to
prolonged abstinence will be tested by the independent
T-test or the Wilcoxon rank sum test.
All analyses will be performed based on the intention-to-
treat principle and will be performed in SPSS version 20.0.
Discussion
To the best of our knowledge, this RCT will be the first
study to examine the effectiveness of a blended smoking
cessation treatment compared to purely face-to-face
treatment. It will also be the first study to explore
patient satisfaction, adherence, cost-effectiveness, and
active ingredients of a blended smoking cessation treat-
ment. The main three strengths of the LiveSmokefree
Study are: (1) The blended smoking cessation treatment
explored in this study was developed by a team in which
all relevant stakeholder actively participated; (2) it dem-
onstrates high ecological validity involving the heteroge-
neous population of regular patients of an outpatient
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smoking cessation clinic; and (3) it includes a long term
biochemically validated follow-up assessment. Main
objective is to test whether face-to-face-smoking cessa-
tion treatment can be substituted by a less demanding
and more patient-friendly blended treatment with simi-
lar outcomes. As our clinical experience with blended
smoking cessation treatment evolves, this trial will
contribute to the understanding of the influence of
blended treatment on both the stop smoking process
and the patient’s experience. The conduct of this trial
and its findings will substantially strengthen the evi-
dence base regarding new delivery modes of smoking
cessation treatment. If blended smoking cessation treat-
ment is shown to be non-inferior on effectiveness while
offering secondary benefits, then dissemination to
clinical practice should be warranted. Such secondary
benefits may be lower treatment costs and higher user
friendliness.
However, there are also limitations in this study. First,
by allowing participants in both arms to opt for one of
three different quitting strategies (stop at once, gradual
change, scheduled reduced smoking), heterogeneity is in-
troduced within the treatment. As allocation to the treat-
ment groups is stratified on this criterion, however, all
three quit strategies will be distributed equally over both
groups and therefore not affect the internal validity of this
trial. As a result, the main objective of this trial, i.e. com-
paring two modes of delivery of a treatment with identical
content and intensity, is safeguarded. External validity
may be somewhat impeded, though, as most cessation
interventions in previous trials do not display such a flex-
ible, preference-based, quit approach. To explore this
issue sub-analyses of program effects among participants
within each quit strategy will be considered, depending on
sufficient sample size within subgroups. Alternately,
moderation by quit strategies or by preference-based
personalization requires testing in a more complex trial
design with multiple study arms in future research.
Despite this obvious limitation, the personalized quit-
ting strategy can also be considered a strength of the
treatment, as it broadens the treatment to a larger target
group and increases the potential reach among smokers.
Another limitation that will merit discussion of the
practical relevance is the rather inflexible approach of
blending in the treatment (five web-based sessions and
five face-to-face sessions in a fixed sequence and with
equivalent content) that is used to allow for comparabil-
ity. This inflexible approach may limit the potential of
blending. Blending web-based and face-to-face interven-
tion could - in extremis - lead to a flexible exchangeabil-
ity of all intervention components, which would foster a
treatment that is highly tailored to the patient’s needs
and abilities. This would allow both the counsellor and
the patient to choose a preferred blend of web-based or
face-to-face delivery, while maintaining efficacy. Future
studies should explore such benefits of flexibly blended
treatment options.
Current status
Recruitment of patients started in May 2015.
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